Similarly, Chowdhury and co-workers [66] designed an in vitro study where they tested different targeted (functionalized with Aptamer-A6) and untargeted liposomal-DOX formulations for the localized treatment of HER2-overexpressing breast cancers. Here, ERBB2 is linked to breast cancer.